Absci Corporation enters the week as one of biotech's more charged setups: a stock up 35% in five days, a short base covering a quarter of the float, and a fresh activist on the register — all heading toward a November earnings print.
The week's most striking tension is the disconnect between price momentum and short conviction. The stock closed Tuesday at $10.71, up 9% on the day alone. Over the past month it has added 12%. Yet short interest has barely flinched — 25.2% of the free float remains short, a level that has barely budged over the past 30 days. Bears have not retreated. If anything, the short base edged up about 2.7% on the week in share terms. With FINRA's most recent official settlement data implying over 12 days to cover, shorts face a real squeeze if buying pressure persists.
The lending market tells a nuanced story. Availability sits at 203% — meaning there are roughly two shares available to borrow for every one currently lent out, which is broadly normal territory and not consistent with an imminent technical squeeze driven by borrow scarcity. Cost to borrow has actually eased sharply this week, falling 35% to just 0.50%. That collapse in borrowing cost, even as the short base holds steady, suggests existing shorts are not under financial pressure to cover — they are sitting on cheap borrows and waiting. Options traders meanwhile are the most bullish they have been in months. The put/call ratio has dropped to 0.12, fractionally below its 20-day mean and not far from the 52-week low of 0.05. That skew is unusually call-heavy for a stock with this level of short interest, pointing to a bifurcated market: shorts dug in via stock, bulls expressing optimism via calls.
The Street is firmly in the bull camp, with eight buy ratings and a consensus target of $14.40 — roughly 34% above Tuesday's close. BTIG raised its target from $13 to $16 in early September, citing the AI-driven drug discovery platform. Needham reiterated its buy this week, holding a $11 target that now sits below the current price — a notable mismatch that reflects how fast the stock has run. LifeSci Capital initiated with Outperform just two weeks ago, adding a fresh institutional voice. The bull case centres on ABS-201, a PRLR-targeting biologic in Phase 1/2a trials for pattern hair loss, with the broader AI-biology platform as the longer-term prize. The bear case is more structural: no revenue, deep losses, a price-to-book approaching 9x, and dependence on third-party manufacturing. The short score from ORTEX sits at 72.9 out of 100, ranking in the bottom 10th percentile of the universe — a signal that the data composite views this as a high-short-pressure name despite the loosening borrow conditions.
The activist register adds another layer. Redmile Group, which filed a Schedule 13D on Absci in April 2025 — signalling active rather than passive intent — most recently disclosed a 4.9% stake, down from 5.4% previously, in an April 2026 amendment. That reduction below the 5% threshold is worth flagging: as is standard with 13D/G disclosures, the stake is "as last disclosed" and Redmile could have exited further without a filing obligation. Meanwhile, institutional momentum has been broad: FMR (Fidelity) holds 14.8% of shares, ARK Investment Management holds 7.5% and added nearly 1.9 million shares in its most recent reported period, and D.E. Shaw nearly quintupled its position in the quarter ending June 30. Columbia Management added 3.8 million shares. The pattern is one of active, growth-oriented managers building or adding — not trimming.
Peer performance this week provides context for the ABSI move. RXRX rose 25% on the week, and VKTX surged 36% in just one session — both correlated names in the AI-biotech and novel-therapeutics space. The broader speculative biotech bid appears broad rather than ABSI-specific, which matters for how durable this week's move proves to be. The last two earnings prints showed a 5.4% next-day gain in August 2026 and an 8.6% jump in May 2026, both followed by mixed five-day returns. With the next earnings date set for November 13, how the short base evolves over the next six weeks — and whether cheap borrow costs attract fresh short supply or finally begin to climb as the stock runs — is the clearest near-term tell.
See the live data behind this article on ORTEX.
Open ABSI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
